{"result": {"id": "19217bae-2819-4beb-a064-3467ea1d89ad", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"CYP3A4 and Drug Metabolism Community\",\n    \"summary\": \"This community centers around CYP3A4, a crucial enzyme in drug metabolism, and its interactions with various drugs including statins, antibiotics, and other medications. The entities within this community are interconnected through metabolic pathways, where CYP3A4 acts as a key player in either the activation or deactivation of drugs, leading to potential drug-drug interactions. The significance of this community lies in its impact on drug efficacy and safety, highlighting the importance of understanding these interactions for clinical decision-making.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the critical role of CYP3A4 in drug metabolism and the potential for significant drug-drug interactions affecting patient safety and treatment outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of CYP3A4 in Drug Metabolism\",\n            \"explanation\": \"CYP3A4 is identified as a central entity in this community, metabolizing a wide range of pharmaceuticals. Its activity can be significantly altered by interactions with other substances, leading to changes in drug efficacy and safety. This enzyme's broad substrate specificity makes it a pivotal factor in pharmacokinetics. [Data: Entities (2070), Relationships (2516, 5220, 5267, 5346, 5154, +more)]\"\n        },\n        {\n            \"summary\": \"Impact of CYP3A4 Inhibitors and Inducers\",\n            \"explanation\": \"Various drugs and substances act as inhibitors or inducers of CYP3A4, affecting the metabolism of co-administered drugs. Inhibitors like clarithromycin and erythromycin can increase the concentration of drugs metabolized by CYP3A4, potentially leading to toxicity. Inducers like rifampin and St. John's Wort can decrease drug concentrations, risking therapeutic failure. [Data: Entities (323, 4944, 4907, 5016), Relationships (5267, 5220, 5346, 5202, +more)]\"\n        },\n        {\n            \"summary\": \"Clinical Implications of Drug-Drug Interactions\",\n            \"explanation\": \"The interactions between CYP3A4 and other drugs have significant clinical implications, including altered drug efficacy, increased risk of adverse effects, and potential treatment failure. For example, the interaction between simvastatin and CYP3A4 inhibitors can increase the risk of muscle toxicity. [Data: Entities (2996, 2070), Relationships (2516, 5267, 5214, +more)]\"\n        },\n        {\n            \"summary\": \"Role of CYP3A4 in Statin Metabolism\",\n            \"explanation\": \"Statins, such as simvastatin, are metabolized by CYP3A4, making their efficacy and safety profile susceptible to changes in CYP3A4 activity. This underscores the need for careful consideration when co-administering statins with CYP3A4 inhibitors or inducers. [Data: Entities (2996, 2070), Relationships (2516, +more)]\"\n        },\n        {\n            \"summary\": \"Importance of Monitoring Drug Interactions\",\n            \"explanation\": \"Given the central role of CYP3A4 in drug metabolism, monitoring for potential drug interactions is crucial in clinical practice. This includes assessing the need for dose adjustments or alternative therapies to avoid adverse outcomes. [Data: Entities (2070, 323, 4907), Relationships (5267, 5220, 5346, +more)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752169011, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 744, "prompt_tokens": 6248, "total_tokens": 6992, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1984}, "prompt_cache_hit_tokens": 1984, "prompt_cache_miss_tokens": 4264}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n3444,吉非罗齐,\"吉非罗齐（Gemfibrozil）是一种贝特类药物，主要用于治疗以三酰甘油（甘油三酯）升高为主的高脂血症，通过降低三酰甘油水平发挥作用。作为CYP2C8抑制剂，吉非罗齐会减慢经该酶代谢的药物（如罗格列酮、吡格列酮和瑞格列奈）的代谢，从而可能增强其药效或延长作用时间。此外，吉非罗齐还能抑制尿苷二磷酸葡萄糖醛酸转移酶（UGT），延缓阿托伐他汀的葡萄糖醛酸化代谢，导致阿托伐他汀的血药浓度-时间曲线下面积（AUC）增加，进而升高肌病风险。  \n\n吉非罗齐与辛伐他汀合用时，会显著增加辛伐他汀的AUC和峰浓度（Cmax），可能引发肌肉毒性，表现为肌酸激酶升高和肌病。因此，临床使用吉非罗齐时需注意药物相互作用，尤其是与他汀类或其他经CYP2C8或UGT代谢的药物联用，以避免不良反应。  \n\n综上所述，吉非罗齐是一种有效的降三酰甘油药物，但其药代动力学特性可能导致多种药物相互作用，需在医生指导下谨慎使用。\",17\r\n3443,非诺贝特,\"**非诺贝特**是一种贝特类药物，化学名称为普鲁脂芬，商品名包括立平脂、苯酰降酯内酯等，主要用于降脂治疗，尤其适用于以三酰甘油（甘油三酯）升高为主的高脂血症。作为治疗高三酰甘油血症的首选药物，其作用机制主要为显著降低血液中的三酰甘油水平。  \n\n非诺贝特的常规剂量为0.1克/次，每日2次，但停药后可能出现血脂反弹现象。该药物不良反应较少，但部分患者可能出现胃肠道不适、食欲减退、嗳气、皮疹、白细胞减少或暂时性肝转氨酶升高等症状。相较于其他降脂药物，非诺贝特对UGT（尿苷二磷酸葡萄糖醛酸转移酶）和CYP2C8（细胞色素P450 2C8酶）无抑制作用，因此药物相互作用极少见，临床安全性较高。  \n\n综合来看，非诺贝特是一种高效且耐受性良好的降脂药物，尤其适用于三酰甘油升高的患者，但需注意其潜在不良反应及停药后可能出现的血脂反弹问题。\",13\r\n2996,辛伐他汀,\"辛伐他汀（Simvastatin），也被称为舒降之，是一种中等强度的他汀类药物，主要用于胆固醇管理和血脂调节。该药物在降低总胆固醇、低密度脂蛋白胆固醇（LDL-C）方面效果显著，同时能适度降低三酰甘油（甘油三酯）水平，并提高高密度脂蛋白胆固醇（HDL-C）。  \n\n辛伐他汀适用于治疗高胆固醇血症以及以胆固醇升高为主的混合型高脂血症。其标准剂量范围为5～20毫克，通常每晚服用一次。临床研究表明，长期服用（如每晚10毫克，持续1年）不仅能有效降低胆固醇和三酰甘油水平，还能缩小动脉内膜的粥样硬化斑块，从而减少心血管疾病风险。  \n\n作为一种降脂药物，辛伐他汀通过抑制HMG-CoA还原酶来减少胆固醇合成，进而改善血脂代谢。其疗效和安全性使其成为高脂血症患者的常用治疗选择之一。\",29\r\n2070,CYP3A4,\"**CYP3A4** is a crucial member of the cytochrome P450 enzyme family, primarily functioning as a drug-metabolizing enzyme in the liver. It plays a central role in the metabolism of a wide variety of pharmaceuticals, including statins (e.g., certain cholesterol-lowering drugs), beta-blockers, sedative-hypnotics, antidepressants, and R-warfarin. As the predominant enzyme in the CYP3A subfamily, CYP3A4 is highly influential in determining drug efficacy and safety.  \n\nCYP3A4 activity can be significantly altered by interactions with other substances. For instance, its function is inhibited by calcium channel blockers (e.g., amlodipine), strong antifungal agents (e.g., posaconazole and clarithromycin), and natural products like grapefruit juice, which can lead to elevated drug concentrations and potential toxicity. Conversely, CYP3A4 induction may reduce drug efficacy or cause fluctuations in blood pressure due to accelerated metabolism.  \n\nWhile some descriptions emphasize its role in metabolizing specific drugs (e.g., R-warfarin or statins), others highlight its broad involvement in drug metabolism. These variations reflect CYP3A4's diverse substrate specificity rather than contradictions. Overall, CYP3A4 is a key enzyme in pharmacokinetics, with its inhibition or induction having significant clinical implications for drug interactions and therapeutic outcomes.\",60\r\n4907,利福平,\"利福平（Rifampin）是一种广谱抗生素，同时也是一种强效的酶诱导剂，对多种药物代谢酶和转运蛋白具有显著影响。它主要通过诱导CYP3A4和CYP450酶系统，加速其他药物的代谢，从而降低其血药浓度和疗效。例如，利福平可降低唑吡坦（zolpidem）的浓度，并加快硝苯地平和胺碘酮（amiodarone）、替格瑞洛（ticagrelor）等药物的代谢。此外，利福平还是一种P-糖蛋白（P-gp）诱导剂，与利格列汀或维格列汀合用时可能减弱这两种降糖药的效果。  \n\n综合来看，利福平的酶诱导作用广泛，可能影响多种药物的疗效，临床联合用药时需特别注意药物相互作用的风险。其机制主要包括加速药物代谢（如CYP3A4和CYP450底物）及增加药物外排（如P-gp底物）。因此，在同时使用利福平和其他药物时，建议监测血药浓度或调整剂量以避免治疗失败。\",12\r\n323,克拉霉素,\"克拉霉素（Clarithromycin）是一种抗生素，同时也是一种强效的CYP3A4/5和P-糖蛋白（P-gp）抑制剂。它通过抑制CYP3A4酶和P-糖蛋白的活性，可能显著减缓其他依赖这些途径代谢的药物的清除率，从而增加其血药浓度，导致潜在的药物相互作用和不良反应。  \n\n例如，克拉霉素与秋水仙碱之间存在严重的药物相互作用，因此使用克拉霉素的患者应禁用秋水仙碱，以避免毒性风险。此外，克拉霉素与格列本脲合用时可能增强后者的降血糖作用，增加低血糖发生的风险。  \n\n综上所述，克拉霉素不仅具有抗菌作用，还具有显著的药酶和转运蛋白抑制作用，临床使用时需特别注意其与其他药物的相互作用，尤其是经CYP3A4代谢或依赖P-糖蛋白转运的药物，以避免不良后果。\",9\r\n5016,圣约翰草提取物,St. John's Wort is a strong CYP3A4 inducer that can decrease zolpidem concentrations,8\r\n4908,硝苯地平,\"硝苯地平是一种钙通道阻滞剂（CCB）类药物，主要用于治疗高血压和心绞痛等心血管疾病。它通过抑制钙离子进入血管平滑肌细胞，从而扩张血管、降低血压。硝苯地平的主要代谢途径是通过细胞色素P450酶系统中的CYP3A4酶进行代谢，这一特性使其容易受到其他药物或食物的影响。  \n\n硝苯地平与某些药物或食物存在显著的相互作用。例如，利福平（一种强效CYP3A4诱导剂）可能加速硝苯地平的代谢，导致其血药浓度降低，从而减弱疗效。相反，葡萄柚汁中的成分可抑制CYP3A4活性，可能增加硝苯地平的血药浓度，进而引发低血压等不良反应。因此，患者在服用硝苯地平时需避免与这些物质同时使用，或在医生指导下调整剂量。  \n\n综上所述，硝苯地平是一种依赖CYP3A4代谢的CCB类药物，其疗效和安全性易受药物相互作用影响，需密切监测以避免潜在风险。\",6\r\n4954,红霉素,\"红霉素（Erythromycin）是一种抗生素，具有显著的药物代谢抑制作用。作为强效的CYP3A4酶抑制剂，红霉素能够减缓多种通过该酶代谢的药物的清除过程，从而可能增加其血药浓度及潜在不良反应风险。例如，红霉素通过抑制CYP3A4显著减慢非洛地平的代谢，延长其作用时间；同时，它还能抑制P-糖蛋白（P-gp）的功能，进一步影响药物分布。  \n\n此外，红霉素与辛伐他汀合用时，因抑制CYP3A4介导的代谢途径，可能导致辛伐他汀血药浓度升高，增加横纹肌溶解症等严重不良反应的风险。这一机制也适用于其他依赖CYP3A4代谢的药物，凸显了红霉素在联合用药时需谨慎评估药物相互作用的重要性。  \n\n综上，红霉素的抗菌作用之外，其药理学特性使其成为临床中需密切监测的药物相互作用因素，尤其在联合使用CYP3A4或P-gp底物药物时，需调整剂量或选择替代方案以规避风险。\",5\r\n4985,替格瑞洛,\"Ticagrelor is an antiplatelet drug whose metabolism is affected by CYP3A4 inhibitors and inducers\"\"\",3\r\n4986,利伐沙班,\"Rivaroxaban is an anticoagulant metabolized by CYP3A4 and CYP2J2, with increased bleeding risk when combined with strong CYP3A4 inhibitors\"\"\",3\r\n5069,贯叶金丝桃,,3\r\n4944,ERYTHROMYCIN,Erythromycin is a strong CYP3A4 inhibitor,2\r\n5086,替利霉素,\"替利霉素（Telithromycin）是一种强效的CYP3A4/5抑制剂药物。作为大环内酯类抗生素的衍生物，它通过显著抑制CYP3A4和CYP3A5酶的活性，影响其他通过该代谢途径的药物的清除率，可能导致药物相互作用和血药浓度升高。两项描述均强调了其对CYP3A4的强抑制作用，其中第二条进一步明确其属于“强抑制剂药物”类别，而第一条补充了其对CYP3A5的抑制效应。综合来看，替利霉素的代谢抑制特性在临床应用中需特别注意，尤其在联合用药时需评估潜在风险。  \n\n（注：原文描述无矛盾，信息互为补充；总字数符合要求，采用第三人称客观表述。）\",2\r\n5087,阿扎那韦,\"阿扎那韦（Atazanavir）是一种强效的CYP3A4/5抑制剂。该药物通过显著抑制CYP3A4和CYP3A5酶的活性，影响其他通过这些酶代谢的药物的清除率，可能导致其血药浓度升高，从而增加不良反应或药物相互作用的风险。这一特性在临床用药中需特别注意，尤其是在联合使用其他依赖CYP3A4/5代谢的药物时。  \n\n两份描述均明确指出阿扎那韦对CYP3A4的强抑制作用，其中一份进一步扩展了其抑制范围至CYP3A5，但两者并无矛盾，而是互为补充。因此，综合来看，阿扎那韦是一种对CYP3A4和CYP3A5均具有强抑制作用的药物。\",2\r\n5088,茚地那韦,\"茚地那韦（Indinavir）是一种药物，已知对细胞色素P450酶系统中的CYP3A4/5亚型具有强效抑制作用。多份描述均明确指出其作为CYP3A4强抑制剂的特性，表明该药物可能显著影响经CYP3A4代谢的其他药物的药代动力学，导致血药浓度升高或毒性风险增加。两份描述内容一致，均强调了茚地那韦在药物相互作用中的关键作用，临床使用时需特别注意联合用药的潜在风险。  \n\n（注：总字数控制在500字内，当前摘要已完整涵盖所有输入信息，无矛盾需调和。）\",2\r\n5089,奈非那韦,\"奈非那韦 (Nelfinavir) is a potent inhibitor of the cytochrome P450 enzyme CYP3A4/5. It is consistently described as a strong or potent inhibitor of this enzyme, which plays a critical role in drug metabolism. The descriptions emphasize its significant inhibitory effect on CYP3A4, with one source specifying its impact on both CYP3A4 and CYP3A5 isoforms. There are no contradictions in the provided descriptions, as both confirm 奈非那韦's role as a CYP3A4 inhibitor, with one providing additional detail about its effect on CYP3A5. This property of 奈非那韦 is important in pharmacokinetics, as it may lead to drug-drug interactions by altering the metabolism of co-administered medications that are substrates of CYP3A4/5.\",2\r\n5090,利托那韦,\"利托那韦（Ritonavir）是一种强效的CYP3A4/5抑制剂。作为蛋白酶抑制剂类药物，它通过显著抑制肝脏和肠道中的CYP3A4酶活性，影响其他通过该酶代谢的药物的清除率，从而增强其药效或延长作用时间。这一特性使其在临床中常被用作药代动力学增强剂，尤其是与其他抗逆转录病毒药物联用时。  \n\n两份描述均明确指出利托那韦对CYP3A4的强抑制作用，且表述一致，未出现矛盾。其中，\"\"CYP3A4/5\"\"的提法更全面，表明其对CYP3A4及其亚型CYP3A5均具有抑制能力，而\"\"CYP3A4强抑制剂药物\"\"的表述则进一步强调了抑制强度的临床意义。综合来看，利托那韦的核心药理特性是通过抑制CYP3A4/5介导的药物代谢，从而调节联合用药的疗效与安全性。  \n\n（注：因输入信息仅涉及药理机制，未包含适应症、副作用等其他细节，故摘要限于此部分内容。）\",2\r\n5091,沙奎那韦,\"沙奎那韦（Saquinavir）是一种强效的CYP3A4/5抑制剂药物。作为蛋白酶抑制剂类抗逆转录病毒药物，其主要通过抑制人体细胞色素P450酶系统中的CYP3A4和CYP3A5亚型发挥作用。这一特性在药物相互作用中具有重要意义，因为CYP3A4/5是肝脏和肠道中代谢多种药物的关键酶，沙奎那韦的抑制作用可能影响其他通过该途径代谢药物的血药浓度。两份描述均明确指出其强效抑制特性，其中第二份中文描述特别强调了\"\"CYP3A4强抑制剂\"\"的定位，而第一份英文描述则扩展了抑制范围至CYP3A5亚型。综合来看，沙奎那韦对CYP3A4的强效抑制作用已形成共识，同时其对CYP3A5的抑制能力也被明确记载。这种双重抑制特性使其在临床应用中需要特别注意潜在的药物相互作用风险。\",2\r\n4883,那格列奈,\"那格列奈（Nateglinide）是一种口服降糖药，属于格列奈类药物。其主要通过细胞色素P450酶系统中的CYP2C9和CYP3A4代谢。作为一种速效胰岛素促泌剂，那格列奈通过刺激胰腺β细胞释放胰岛素来帮助控制血糖水平，尤其适用于2型糖尿病患者的餐后血糖管理。  \n\n两种描述均明确指出那格列奈的代谢途径依赖CYP2C9和CYP3A4酶，且其药理分类为格列奈类降糖药。尽管表述语言不同（中英文），但核心信息一致，无矛盾。综合来看，那格列奈的作用机制和代谢特性使其成为糖尿病治疗中针对餐后高血糖的针对性药物，但需注意与其他通过相同酶代谢的药物可能存在的相互作用。\",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n3210,吉非罗齐,高脂血症,吉非罗齐用于治疗以三酰甘油升高为主的高脂血症。,251\r\n3209,非诺贝特,高脂血症,非诺贝特用于治疗以三酰甘油升高为主的高脂血症。,247\r\n2516,辛伐他汀,CYP3A4,\"辛伐他汀（Simvastatin）是一种降胆固醇药物，其代谢过程主要依赖于细胞色素P450酶系统中的CYP3A4同工酶。CYP3A4在辛伐他汀的生物转化中起关键作用，负责其代谢清除。研究表明，多种药物可通过抑制CYP3A4的活性而影响辛伐他汀的代谢速率，可能导致辛伐他汀的血药浓度升高，从而增加不良反应风险。这一代谢途径的明确对于临床用药具有重要指导意义，尤其在联合用药时需注意潜在的药物相互作用。  \n\n（注：总结严格遵循了以下要求：1. 合并所有描述信息；2. 以第三人称客观表述；3. 包含全部实体名称；4. 无矛盾表述；5. 字数控制在500字内。）\",89\r\n5220,利福平,CYP3A4,利福平 induces CYP3A4 enzyme activity,72\r\n5267,克拉霉素,CYP3A4,克拉霉素抑制CYP3A4酶活性,69\r\n5346,圣约翰草提取物,CYP3A4,圣约翰草提取物是一种典型的CYP3A4和P-糖蛋白（P-gp）诱导剂，能够显著增强CYP3A4酶的活性。这种诱导作用导致圣约翰草提取物与多种药物之间存在具有临床意义的相互作用。由于CYP3A4是人体内重要的药物代谢酶，其活性的增强可能加速其他通过该酶代谢的药物的清除，从而降低这些药物的疗效或缩短其作用时间。因此，圣约翰草提取物与依赖CYP3A4代谢的药物联合使用时需谨慎，以避免潜在的疗效减弱或治疗失败。,68\r\n5154,CYP3A4,硝苯地平,硝苯地平主要经CYP3A4代谢,66\r\n5214,红霉素,CYP3A4,红霉素 inhibits CYP3A4 enzyme activity,65\r\n5292,替格瑞洛,CYP3A4,\"CYP3A4 metabolizes ticagrelor, affecting its antiplatelet activity\",63\r\n5294,利伐沙班,CYP3A4,\"Rivaroxaban is metabolized by CYP3A4, increasing bleeding risk with inhibitors\nCYP3A4 metabolizes rivaroxaban, increasing bleeding risk with inhibitors\",63\r\n5407,CYP3A4,贯叶金丝桃,贯叶金丝桃含有CYP3A4诱导剂成分,63\r\n5202,CYP3A4,ERYTHROMYCIN,Erythromycin inhibits CYP3A4,62\r\n5431,CYP3A4,替利霉素,替利霉素是CYP3A4的强抑制剂,62\r\n5432,CYP3A4,阿扎那韦,阿扎那韦是CYP3A4的强抑制剂,62\r\n5433,CYP3A4,茚地那韦,茚地那韦是CYP3A4的强抑制剂,62\r\n5434,CYP3A4,奈非那韦,奈非那韦是CYP3A4的强抑制剂,62\r\n5435,CYP3A4,利托那韦,利托那韦是CYP3A4的强抑制剂,62\r\n5436,CYP3A4,沙奎那韦,沙奎那韦是CYP3A4的强抑制剂,62\r\n5484,那格列奈,CYP3A4,那格列奈 is metabolized by CYP3A4,62\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_dfd50c1dfc888cedbc371a4cb406336ffffe046c64364dc9748c4f89b083d91f_v2"}